Paul G. Richardson, MD, on a Novel Immunotherapy Plus Dexamethasone in Relapsed or Refractory Myeloma

Posted: Monday, July 13, 2020

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses a novel cereblon E3 ubiquitin ligase-modulating agent, CC-92480, combined with dexamethasone in a first-in-human phase I study of patients with relapsed or refractory myeloma. Overall responses were observed, even among heavily pretreated patients.